First Line Systemic Treatment | List of Frontiers open access articles

Clinical Case Study

Published on 26 Oct 2012

Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report

in Cancer Immunity and Immunotherapy

Anabella Llanos
Mariana Savignano
Gabriela Cinat

Frontiers in Oncology

doi 10.3389/fonc.2012.00152

6,841 views
5 citations

Systematic Review

Published on 24 Dec 2021

First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

in Cancer Molecular Targets and Therapeutics

Wenfeng Liu
Bing Quan
Shenxin Lu
Bei Tang
Miao Li
Rongxin Chen
Zhenggang Ren
Xin Yin

Frontiers in Oncology

doi 10.3389/fonc.2021.771045

13,918 views
29 citations

Original Research

Published on 31 Jul 2020

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients

in Women's Cancer

Yujie Lu
Yiwei Tong
Jiahui Huang
Lin Lin
Jiayi Wu
Xiaochun Fei
Ou Huang
Jianrong He
Li Zhu
Weiguo Chen

Frontiers in Oncology

doi 10.3389/fonc.2020.01315

3,300 views
3 citations

Case Report

Published on 19 Sep 2025

SFRT combined with immunotherapy for a growing hepatocellular carcinoma after the failure of anti-angiogenesis and anti-PD1 treatment: a case report

in Radiation Oncology

Jiamiao Hu
Yue Jin
Mengjia Wang
Yuke Pang
Shenkangle Wang
Xuyun Xie
Zhewen Wang
Xiaonan Sun

Frontiers in Oncology

doi 10.3389/fonc.2025.1591424

2,967 views

Review

Published on 15 Oct 2024

Systemic treatments for radioiodine-refractory thyroid cancers

in Thyroid Endocrinology

Piaohong Chen
Yu Yao
Huiwen Tan
Jianwei Li

Frontiers in Endocrinology

doi 10.3389/fendo.2024.1346476

6,879 views
11 citations

Original Research

Published on 09 Nov 2022

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

in Pharmacogenetics and Pharmacogenomics

Evelien G. E. Hurkmans
Jan B. Koenderink
Jeroen J. M. W. van den Heuvel
Yvonne M. H. Versleijen-Jonkers
Melissa H. S. Hillebrandt-Roeffen
Johanne M. Groothuismink
Hanneke I. Vos
Winette T. A. van der Graaf
Uta Flucke
Grigor Muradjan

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1042989

4,867 views
6 citations

Original Research

Published on 29 Sep 2022

The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study

in Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Zheng Guo
Huabin Zhu
Xiufang Zhang
Li Huang
Xiangcai Wang
Huaqiu Shi
Li Yu
Yingwei Qiu
Fuping Tu

Frontiers in Oncology

doi 10.3389/fonc.2022.941068

2,947 views
7 citations

Articles

Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report

First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients

SFRT combined with immunotherapy for a growing hepatocellular carcinoma after the failure of anti-angiogenesis and anti-PD1 treatment: a case report

Systemic treatments for radioiodine-refractory thyroid cancers

SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

The efficacy and safety of conventional transcatheter arterial chemoembolization combined with PD-1 inhibitor and anti-angiogenesis tyrosine kinase inhibitor treatment for patients with unresectable hepatocellular carcinoma: a real-world comparative study